
Edgewise’s Sevasemten Shows Positive Two-Year Results in Becker Muscular Dystrophy Trial
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company specializing in muscle diseases, has unveiled encouraging two-year topline results from the ARCH trial. The ARCH study, conducted at a single center, is an open-label investigation focusing on assessing safety, tolerability,…












